Carey Douglas Kessler & Ruby PLLC
General
Cases14
Challenger50%
Patent Owner50%
NPE50%
--
--
Practice Areas
BiotechMech Eng, ManufChemical
Top Attorneys
Elite Ratings
DCTPTABCAFC
Analytics
Lawyers
Cases
Ratings Trends
Practice Areas
Recent Dockets
Entered | Case | Description |
---|---|---|
02/10/25 | STIPULATION AND ORDER ENLARGING TIME TO FILE RESPONSE AND REPLY MEMORANDA TO PLALINTIFF'S MOTION TO STRIKE DEFENDANT'S INEQUITABLE CONDUCT AFFIRMATIVE DEFENSES AND TO DISMISS DEFENDANT'S INEQUITABLE COUNTERCLAIMS by Sandoz Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:24-cv-00085-TSK(Wakefield, Jeffrey) (Entered: 02/10/2025) | |
01/29/25 | USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025) | |
01/29/25 | OPINION of USCA for the FEDERAL CIRCUIT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD., (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA for the FEDERAL CIRCUIT Decision: AFFIRMED. (snc) (Entered: 01/29/2025) | |
01/29/25 | USCA for the FEDERAL CIRCUIT JUDGMENT as to (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG. (snc) (Entered: 01/29/2025) | |
01/29/25 | OPINION of USCA for the FEDERAL CIRCUIT as to (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG USCA Decision: AFFIRMED. (snc) (Entered: 01/29/2025) | |
01/29/25 | USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025) | |
01/29/25 | OPINION of USCA for the FEDERAL CIRCUIT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD., (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA for the FEDERAL CIRCUIT Decision: AFFIRMED. (snc) (Entered: 01/29/2025) | |
01/29/25 | USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025) | |
01/29/25 | OPINION of USCA for the FEDERAL CIRCUIT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD., (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. USCA for the FEDERAL CIRCUIT Decision: AFFIRMED. (snc) (Entered: 01/29/2025) | |
01/29/25 | USCA JUDGMENT as to (344 in 1:24-md-03103-TSK-JPM, 258 in 1:24-cv-00039-TSK-JPM) Notice of Appeal filed by Regeneron Pharmaceuticals, Inc., (250 in 1:23-cv-00106-TSK-JPM, 259 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Samsung Bioepis Co., Ltd., (801 in 1:22-cv-00061-TSK-JPM, 190 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., (269 in 1:24-md-03103-TSK-JPM, 204 in 1:23-cv-00089-TSK-JPM) Notice of Appeal, filed by Celltrion, Inc., (258 in 1:24-md-03103-TSK-JPM, 268 in 1:23-cv-00094-TSK-JPM) Notice of Appeal filed by Samsung Bioepis, CO., LTD.,, (244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD.,, (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG, (254 in 1:23-cv-00097-TSK-JPM, 261 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Formycon AG, (176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis Co., Ltd., (198 in 1:23-cv-00089-TSK-JPM, 241 in 1:24-md-03103-TSK-JPM) Notice of Appeal filed by Celltrion, Inc. (snc) (Entered: 01/29/2025) |